Compare Agilysys Inc (AGYS) vs Amgen, Inc. (AMGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilysys Inc vs Amgen, Inc. — how do they compare? Agilysys Inc trades at $105.38 (market cap $3.00B), while Amgen, Inc. trades at $417.44 (market cap $224.14B). The key difference: Amgen, Inc. is far larger — about 74.7× Agilysys Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Agilysys Inc pays none. Which is the better fit depends on your goals.
| AGYS | AMGN | |
|---|---|---|
Market Cap | $3.00B | $224.14B |
Sector | Technology | Health |
52-Week High | $141.12 | $417.20 |
52-Week Low | $62.19 | $271.18 |
Enterprise Value | $2.90B | $267.45B |
Dividend Yield | — | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilysys (AGYS) trades at $104.92, down 1.93% on the day, with a bullish technical signal and strong analyst support. Recent Q1 2027 earnings beat expectations, driven by subscription growth and record revenue, prompting raised full-year guidance. The stock shows robust fundamentals with a 63.06% gross margin and 12.99% net income margin, though valuations are elevated with a P/E of 70.01. Institutional sentiment is positive, with all 9 analysts rating it a Buy and a consensus price target of $118.33.
Outlook remains favorable due to earnings momentum and AI-driven hospitality solutions, but risks include high valuation sensitivity and competitive pressures. Upside potential is supported by analyst targets, yet investors should monitor execution on growth forecasts and market volatility.
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilysys Inc
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
